JP2015524808A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524808A5
JP2015524808A5 JP2015524450A JP2015524450A JP2015524808A5 JP 2015524808 A5 JP2015524808 A5 JP 2015524808A5 JP 2015524450 A JP2015524450 A JP 2015524450A JP 2015524450 A JP2015524450 A JP 2015524450A JP 2015524808 A5 JP2015524808 A5 JP 2015524808A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
apolipoprotein
administered
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015524450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524808A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/052078 external-priority patent/WO2014018763A2/en
Publication of JP2015524808A publication Critical patent/JP2015524808A/ja
Publication of JP2015524808A5 publication Critical patent/JP2015524808A5/ja
Pending legal-status Critical Current

Links

JP2015524450A 2012-07-25 2013-07-25 アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法 Pending JP2015524808A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675659P 2012-07-25 2012-07-25
US61/675,659 2012-07-25
PCT/US2013/052078 WO2014018763A2 (en) 2012-07-25 2013-07-25 Method of treating type i diabetes using apolipoprotein aiv

Publications (2)

Publication Number Publication Date
JP2015524808A JP2015524808A (ja) 2015-08-27
JP2015524808A5 true JP2015524808A5 (enExample) 2016-08-25

Family

ID=48916270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015524450A Pending JP2015524808A (ja) 2012-07-25 2013-07-25 アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法

Country Status (6)

Country Link
US (1) US9730980B2 (enExample)
EP (1) EP2877197A2 (enExample)
JP (1) JP2015524808A (enExample)
AU (1) AU2013295721B2 (enExample)
CA (1) CA2878695A1 (enExample)
WO (1) WO2014018763A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342020B (es) 2011-01-19 2016-09-08 Univ Cincinnati Apolipoproteina a-iv como un peptido antidiabetico.
HK1203823A1 (en) 2012-01-19 2015-11-06 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2014018079A1 (en) 2012-07-25 2014-01-30 University Of Cincinnati Method of treating hyperglycemic disorders using apoliprotein aiv

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2686605B1 (fr) 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
AU7242394A (en) 1993-05-28 1994-12-20 Merck & Co., Inc. Method to control appetite and treat obesity
CA2453653A1 (en) * 2001-07-26 2003-02-06 Genset S.A. Gmg-2 polynucleotides and polypeptides and uses thereof
IL161233A0 (en) * 2001-10-05 2004-09-27 Genset Sa Fragments of the polypeptide gzip and their use in obesity
NZ537006A (en) 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
RU2006134701A (ru) * 2004-03-01 2008-04-10 Пептиммьюн Способы и композиции для лечения аутоиммунных заболеваний
TW200815377A (en) * 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
EP2257814B1 (en) 2008-03-21 2012-08-29 Podiceps B.v. Diagnostic of pre-symptomatic metabolic syndrome
CN101747305B (zh) 2008-11-28 2014-06-18 中国医学科学院药物研究所 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
DK2498802T3 (en) * 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
MX342020B (es) * 2011-01-19 2016-09-08 Univ Cincinnati Apolipoproteina a-iv como un peptido antidiabetico.
HK1203823A1 (en) 2012-01-19 2015-11-06 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2014018079A1 (en) 2012-07-25 2014-01-30 University Of Cincinnati Method of treating hyperglycemic disorders using apoliprotein aiv

Similar Documents

Publication Publication Date Title
JP2011241213A5 (enExample)
JP2013507439A5 (enExample)
JP2016539921A5 (enExample)
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
RU2600440C3 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
HRP20170358T1 (hr) Inhibitori histonskih demetilaza
JP2014521684A5 (enExample)
HRP20251088T1 (hr) Upotreba dugodjelujućih peptida glp‑1
JP2014526441A5 (enExample)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
JP2015518818A5 (enExample)
RU2739037C3 (ru) Композиция для контролируемой стимуляции яичников
JP2011526886A5 (enExample)
RU2016119746A (ru) Стабильный состав инсулина глулизин
JP2011519364A5 (enExample)
JP2015517488A5 (enExample)
TR201815158T4 (tr) Selektif glukagon reseptör agonistleri olarak eksendin-4 deriveleri.
JP2013542247A5 (enExample)
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
JP2014504601A5 (enExample)
JP2014532722A5 (enExample)
RU2016114098A (ru) Новое производное аналога инсулина
IN2014DN06920A (enExample)